# 1 **Association of Structural Forms of 17q21.31 with the Risk of Progressive**  2 **Supranuclear Palsy and** *MAPT* **Sub-haplotypes**

3 Hui Wang<sup>1,2</sup>, PhD; Timothy S Chang<sup>3</sup>, MD, PhD; Beth A Dombroski<sup>1,2</sup>, PhD; Po-Liang Cheng<sup>1,2</sup>, PhD; 4 Ya-Qin Si<sup>4</sup>, PhD; Albert Tucci<sup>4</sup>, PhD; Vishakha Patil<sup>5</sup>, MS; Leopoldo Valiente-Banuet<sup>5</sup>, MS; Kurt 5 Farrell<sup>6</sup>, PhD; Catriona Mclean<sup>7</sup>, MD; Laura Molina-Porcel<sup>8,9</sup>, MD, PhD; Alex Rajput<sup>10</sup>, MD; Peter Paul 6 De Deyn<sup>11,12</sup>, MD, PhD; Nathalie Le Bastard<sup>13</sup>, PhD; Marla Gearing<sup>14</sup>, PhD; Laura Donker Kaat<sup>15</sup>, MD, 7 PhD; John C Van Swieten<sup>15</sup>, MD, PhD; Elise Dopper<sup>15</sup>, MD, PhD; Bernardino F Ghetti<sup>16</sup>, MD; Kathy L 8 Newell<sup>16</sup>, MD; Claire Troakes<sup>17</sup>, PhD; Justo G de Yébenes<sup>18</sup>, MD, PhD; Alberto Rábano-Gutierrez<sup>19</sup>, 9 MD, PhD; Tina Meller<sup>20</sup>, PhD; Wolfgang H Oertel<sup>20</sup>, MD, PhD; Gesine Respondek<sup>21</sup>, MD; Maria 10 Stamelou<sup>22,23</sup>, MD; Thomas Arzberger<sup>24,25</sup>, MD; Sigrun Roeber<sup>26</sup>, MD; Ulrich Müller<sup>26</sup>, MD; Franziska 11 Hopfner<sup>44</sup>, MD; Pau Pastor<sup>27,28</sup>, MD, PhD; Alexis Brice<sup>29</sup>, MD; Alexandra Durr<sup>29</sup>, MD, PhD; Isabelle Le 12 Ber<sup>29</sup>, MD, PhD; Thomas G Beach<sup>30</sup>, MD, PhD; Geidy E Serrano<sup>30</sup>, PhD; Lili-Naz Hazrati<sup>31</sup>, MD, PhD; 13 Irene Litvan<sup>32</sup>, MD; Rosa Rademakers<sup>33,34</sup>, PhD; Owen A Ross<sup>34</sup>, PhD; Douglas Galasko<sup>32</sup>, MD; Adam 14 L Boxer<sup>35</sup>, MD, PhD; Bruce L Miller<sup>35</sup>, MD; Willian W Seeley<sup>35</sup>, MD; Vivianna M Van Deerlin<sup>1</sup>, MD, 15 PhD; Edward B Lee<sup>1,36</sup>, MD, PhD; Charles L White  $III^{37}$ , MD; Huw R Morris<sup>38</sup>, MD, PhD; Rohan de 16 Silva<sup>39</sup>, PhD; John F Crary<sup>6</sup>, MD, PhD; Alison M Goate<sup>40</sup>, PhD; Jeffrey S Friedman<sup>41</sup>, MD, PhD; Yuk 17 Yee Leung<sup>1,2</sup>, PhD; Giovanni Coppola<sup>5,42</sup>, MD; Adam C Naj<sup>1,2,43</sup>, PhD; Li-San Wang<sup>1,2</sup>, PhD; PSP 18 genetics study group; Dennis W Dickson<sup>34</sup>, MD; Günter U Höglinger<sup>44</sup>, MD; Jung-Ying Tzeng<sup>4,45</sup>, PhD; 19 Daniel H Geschwind<sup>5,46,47</sup>, MD, PhD; Gerard D Schellenberg<sup>1,2</sup>, PhD; Wan-Ping Lee<sup>1,2</sup>, PhD 20

- <sup>1</sup> Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of 22 Pennsylvania, Philadelphia, PA, USA
- 23 <sup>2</sup>Penn Neurodegeneration Genomics Center, Perelman School of Medicine, University of Pennsylvania, 24 Philadelphia, PA, USA
- <sup>3</sup> 3 Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine,
- 26 University of California, Los Angeles, Los Angeles, CA, USA
- 27 <sup>4</sup> Bioinformatics Research Center, North Carolina State University, NC, USA
- <sup>28</sup> Movement Disorders Programs, Department of Neurology, David Geffen School of Medicine,
- 29 University of California, Los Angeles, Los Angeles, CA, USA

- <sup>6</sup> 30 Department of Pathology, Department of Artificial Intelligence & Human Health, Nash Family,
- 31 Department of Neuroscience, Ronald M. Loeb Center for Alzheimer's Disease, Friedman Brain,
- 32 Institute, Neuropathology Brain Bank & Research CoRE, Icahn School of Medicine at Mount Sinai,
- 33 New York, NY, USA.
- <sup>7</sup> Victorian Brain Bank, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, 35 Australia
- <sup>8</sup> 36 Alzheimer's disease and other cognitive disorders unit. Neurology Service, Hospital Clínic,
- 37 Fundació Recerca Clínic Barcelona (FRCB). Institut d'Investigacions Biomediques August Pi i Sunyer 38 (IDIBAPS), University of Barcelona, Barcelona, Spain
- <sup>9</sup> Neurological Tissue Bank of the Biobanc-Hospital Clínic-IDIBAPS, Barcelona, Spain
- <sup>10</sup> Movement Disorders Program, Division of Neurology, University of Saskatchewan, Saskatoon,
- 41 Saskatchewan, Canada
- <sup>11</sup> Laboratory of Neurochemistry and Behavior, Experimental Neurobiology Unit, University of Antwerp,
- 43 Wilrijk (Antwerp), Belgium
- <sup>12</sup> Department of Neurology, University Medical Center Groningen, NL-9713 AV Groningen,
- 45 Netherlands
- <sup>13</sup> Fujirebio Europe NV, Technologiepark 6, 9052 Gent, Belgium
- <sup>14</sup> Department of Pathology and Laboratory Medicine and Department of Neurology, Emory University 48 School of Medicine, Atlanta, GA, USA
- <sup>15</sup> Netherlands Brain Bank and Erasmus University, Netherlands
- <sup>16</sup> Department of Pathology and Laboratory Medicine, Indiana University School of Medicine,
- 51 Indianapolis, IN, USA
- 52 <sup>17</sup> London Neurodegenerative Diseases Brain Bank, King's College London, London, UK
- 53 <sup>18</sup> Autonomous University of Madrid, Madrid, Spain
- <sup>19</sup> Fundación CIEN (Centro de Investigación de Enfermedades Neurológicas) Centro Alzheimer
- 55 Fundación Reina Sofía, Madrid, Spain
- <sup>20</sup> 56 Department of Neurology, Philipps-Universität, Marburg, Germany
- $2^{12}$  German Center for Neurodegenerative Diseases (DZNE), Munich, Germany
- <sup>22</sup> Parkinson's disease and Movement Disorders Department, HYGEIA Hospital, Athens, Greece
- $59 \text{ }^{23}$ European University of Cyprus, Nicosia, Cyprus
- <sup>24</sup> Department of Psychiatry and Psychotherapy, University Hospital Munich,
- 61 Ludwig-Maximilians-University Munich, Germany
- <sup>25</sup> Center for Neuropathology and Prion Research, Ludwig-Maximilians-University Munich, Germany
- <sup>26</sup> 63 German Brain Bank, Neurobiobank Munich, Germany
- $2^{7}$ Unit of Neurodegenerative diseases, Department of Neurology, University Hospital Germans Trias i 65 Pujol, Badalona, Barcelona, Spain
- <sup>28</sup> Neurosciences, The Germans Trias i Pujol Research Institute (IGTP) Badalona, Badalona, Spain
- $2^{9}$ Sorbonne Université, Paris Brain Institute Institut du Cerveau ICM, Inserm U1127, CNRS UMR
- 68 7225, APHP Hôpital Pitié-Salpêtrière, Paris, France

- <sup>30</sup> 69 Banner Sun Health Research Institute, Sun City, AZ, USA
- <sup>31</sup> 70 University McGill, Montreal, Quebec, Canada
- <sup>32</sup> Department of Neuroscience, University of California, San Diego, CA, USA
- <sup>33</sup> 72 <sup>33</sup> VIB Center for Molecular Neurology, University of Antwerp, Belgium
- <sup>34</sup> 73 Department of Neuroscience, Mayo Clinic Jacksonville, FL, USA
- <sup>35</sup> Memory and Aging Center, University of California, San Francisco, CA, USA
- <sup>36</sup> Center for Neurodegenerative Disease Research, University of Pennsylvania School of Medicine,
- 76 Philadelphia, PA, USA
- <sup>37</sup> University of Texas Southwestern Medical Center, Dallas, TX, USA
- <sup>38</sup> Departmento of Clinical and Movement Neuroscience, University College of London, London, UK
- <sup>39</sup> Reta Lila Weston Institute, UCL Queen Square Institute of Neurology, London, UK.
- 80 <sup>40</sup> Department of Genetics and Genomic Sciences, New York, NY, USA; Icahn School of Medicine at
- 81 Mount Sinai, New York, NY, USA
- 82 <sup>41</sup> Friedman Bioventure, Inc., Del Mar, CA, USA
- 83 Department of Genetics and Genomic Sciences, New York, NY, USA
- <sup>42</sup> Department of Psychiatry, Semel Institute for Neuroscience and Human Behavior, University of
- 85 California, Los Angeles, CA, USA
- 86 <sup>43</sup>Department of Biostatistics, Epidemiology, and Informatics, Perelman School of Medicine, University 87 of Pennsylvania, Philadelphia, PA, USA
- 88 <sup>44</sup> Department of Neurology, LMU University Hospital, Ludwig-Maximilians-Universität (LMU)
- 89 München; German Center for Neurodegenerative Diseases (DZNE), Munich, Germany; and Munich
- 90 Cluster for Systems Neurology (SyNergy), Munich, Germany
- 91 <sup>45</sup> Department of Statistics, North Carolina State University, NC, USA
- <sup>46</sup> Department of Human Genetics, David Geffen School of Medicine, University of California, Los
- 93 Angeles, Los Angeles, CA, USA
- 94 <sup>47</sup> Institute of Precision Health, University of California, Los Angeles, Los Angeles, CA, USA
- 95

# 96 **Search Terms:**

- 97 Progressive Supranuclear Palsy (PSP), H1 and H2 haplotypes, MAPT, Copy number variation (CNV), 98 17q21.31
- 99
- 100 **Word Count:** 3902 (Key Points, Abstract, and Main Text)
- 101
- 102 **Corresponding Author:**
- 103 Wan-Ping Lee
- 104 D103 Medical Research Laboratories, University of Pennsylvania,
- 105 3700 Hamilton Walk, Philadelphia, PA 19104, USA
- 106 Phone: +1 412-880-8674
- 107 Email: wan-ping.lee@pennmedicine.upenn.edu

108

109 **Statistical Analysis** conducted by Hui Wang, Ph.D., University of Pennsylvania

# 110 **Key Points**



122 factors, including the copy number of γ duplication.

#### 123 **Abstract**



143 with H1 and H2, while the copy number of γ was independently associated with the increased risk of 144 PSP. Each additional duplication of γ was associated with 1.10 (95% CI, 1.04-1.17; *P* = 0.0018) fold of 145 increased risk of PSP when conditioning H1 and H2. For the H1 haplotype, addition γ duplications 146 displayed a higher odds ratio for PSP: the odds ratio increases from 1.21 (95%CI 1.10-1.33,  $P = 5.47 \times$ 147 10<sup>-5</sup>) for H1β1γ1 to 1.29 (95%CI 1.16-1.43,  $P = 1.35 \times 10^{-6}$ ) for H1β1γ2, 1.45 (95%CI 1.27-1.65,  $P =$  $3.94 \times 10^{-8}$ ) for H1 $\beta$ 1y3, and 1.57 (95%CI 1.10-2.26,  $P = 1.35 \times 10^{-2}$ ) for H1 $\beta$ 1y4. Moreover, H1 $\beta$ 1y3 is 149 in linkage disequilibrium with H1c ( $R^2 = 0.31$ ), a widely recognized *MAPT* sub-haplotype associated 150 with increased risk of PSP. The proportion of *MAPT* sub-haplotypes associated with increased risk of 151 PSP (i.e., H1c, H1d, H1g, H1o, and H1h) increased from 34% in H1β1γ1 to 77% in H1β1γ4. <sup>152</sup>**Conclusions and relevance**: This study revealed that the copy number of γ was associated with the risk 153 of PSP independently from H1 and H2. The H1 haplotype with more γ duplications showed a higher 154 odds ratio for PSP and were associated with *MAPT* sub-haplotypes with increased risk of PSP. These 155 findings expand our understanding of how the complex structure at 17q21.31 affect the risk of PSP.

### 156 **Introduction**

157 Progressive supranuclear palsy (PSP) is a neurodegenerative disease with two characteristic clinical 158 features, i.e. postural instability and ocular motor abnormalities<sup>1</sup>. Other symptoms and signs, such as 159 cognitive disfunction and problems with swallowing, vary and can get worse over time depending on the 160 distribution of pathology and severity of diseases<sup>2,3</sup>. The main pathology of PSP is the accumulation of 161 tau in the brain, leading to the presence of neurofibrillary tangles and threads along with tufted 162 astrocytes and oligodendroglial coiled bodies<sup>4,5</sup>. An isoform of tau harboring 4 repeats (4R) of 163 microtubule-binding domain is particularly prominent in these tau aggregates $6$ .

164 The most recognized genetic risk locus for PSP is situated on 17q21.31. The region can be divided into two major haplotypes, H1 and H2, characterized by a 900 Kb inversion found in 20% of Europeans<sup>7</sup>. 166 Individuals carrying the H1 haplotype, compared to the H2 haplotype, are more likely to develop PSP, 167 with an estimated odds ratio (OR) around 5 in Europeans<sup>8,9</sup>. The association was identified through 168 various variants in linkage disequilibrium (LD) with H1 and H2, such as a dinucleotide repeat  $(TG)_{n}$  in 169 *MAPT* intron 9<sup>10</sup>, a 238-bp deletion in *MAPT* intron 9<sup>7</sup>, and a multitude of single nucleotide variants  $(170 \text{ (SNVs)}$  in this region<sup>8,9</sup>. However, the causal variants underlying the association remain unclear due to 171 numerous SNVs, short insertion/deletions (indels), and structural variations (SVs) introduced by 172 complex genomic rearrangements in 17q.21.31.

173 Based on LD structure in the *MAPT* region, H1 and H2 haplotypes can be further categorized into 174 more than 20 common sub-haplotypes $11-13$ . Among them, H1c, H1d, H1g, and H1o were significantly 175 associated with the increased risk of  $PSP<sup>11,13</sup>$ . Particularly, H1c and H1d are nominally associated with



185

#### 186 **Methods**

### 187 *Study subjects and quality control*

188 All study subjects and WGS data are available on The National Institute on Aging Genetics of 189 Alzheimer's Disease Data Storage Site (NIAGADS)<sup>16</sup> under Alzheimer's Disease Sequencing Project 190 (ADSP) Umbrella NG00067. $v7^{17}$ . We inferred ancestry of subjects by GRAF-pop<sup>18</sup> and selected 4,618 191 subjects (1,797 cases and 2,821 controls) of European ancestry for analysis. WGS were performed at 192 30x coverage (e**Table 1**).

193 Among 4,618 samples, we filtered 183 samples with abnormally low reads mapped (aligned read 194 depth < 1.7x) to α, β or γ region (eFigure 2 in **Supplement**) and ten samples with high genotyping 195 missing rate ( $> 0.05$ ). Next, 244 related samples inferred by  $KING<sup>19</sup>$  (duplicates, monozygotic twins,

196 parent-offsprings, full-siblings, and  $2<sup>nd</sup>$  degree relatives) were removed.

197 We used the 238-bp deletion between exons 9 and 10 of *MAPT*<sup>7</sup> to determine the H1 and H2 198 haplotypes of each sample. The genotype calls of the 238-bp deletion were obtained from our previous  $SVM work<sup>20</sup>$ . 75 subjects were removed due to missing or failed genotype of the 238-bp deletion. Given 200 the specification of H1/H2 genotype, determined by the 238 bp deletion, and the copy numbers of  $\alpha$ ,  $\beta$ 201 and γ, we can ascertain the ten structural forms (eFigure 1 in **Supplement**) in each individual. We 202 removed 30 individuals (eFigure 3 and eFigure 4 in **Supplement**) since their structural forms could not 203 be decided based on the copy numbers of  $\alpha$ ,  $\beta$  and  $\gamma$ . This discordance might be due to subjects carrying 204 undiscovered structural forms or genotyping errors on the copy numbers of  $\alpha$ ,  $\beta$  and  $\gamma$ . As a result, 4,076 205 subjects (Table 1; N<sub>PSP</sub> = 1,684, N<sub>control</sub> = 2,392) remained for statistical analyses in this study. Of the 206 1,684 individuals with PSP, 1,386 were autopsy confirmed.



## 207 **Table 1. Characteristics of PSP cases and controls**

208  $\frac{a_{1,130}}{a_{1,130}}$  PSP cases and 111 controls have missing age.

 $\mathrm{^{b}H1/H2}$  status was determined by the genotype of a 238-bp H2 tagging deletion<sup>7</sup>.

 $^{6}$  PH1/H2 status was determined by the genotype of a 238-bp H2 tagging deletion<sup>7</sup>.<br>210 <sup>c</sup> Structural forms of 17q21.31 were inferred by expectation-maximization (EM) algorithm.

#### <sup>211</sup>*Calling the copy numbers* α*,* β *and* γ *duplications from WGS*



223

#### 224 *Validation of CNV calling*

225 To validate the copy numbers of  $\alpha$ ,  $\beta$  and  $\gamma$  called from WGS, 66 samples were genotyped using 226 TaqMan CNV assay. Overall, the copy number of  $\alpha$ ,  $\beta$ , or γ inferred by aligned read depth from WGS 227 were highly consistent (α, R = 0.87; γ, R = 0.96) with that from TaqMan assay (eFigure 6 in <sup>228</sup>**Supplement**). The experimental procedure was as follows: Copy number at the α region (Context 229 Sequence: TTAGTCAATTTCTTAGCCAACCCAT; chr17:46171656-46171680, GRCh38) was 230 determined using a predesigned TaqMan CNV assay (Applied Biosystems Part No. Hs01788222\_cn).

231 Copy number at the γ region (Context Sequence: AGAAAAAAAGCATTGACTCCAACCC; 232 chr17:46419867-46419891 and chr17:46637445-46637469, GRCh38) was determined using a custom 233 designed TaqMan CNV assay (Applied Biosystems; Forward Primer: 234 TGGCACAATGACCATCGAGATT, Reverse Primer: CTGCCATCTTGTCGGTGTCA, Reporter 235 Sequence: AAGGGTTGGAGTCAATGCTTTT). For the copy number assay reaction, 20 ng of genomic 236 DNA was combined with TaqMan Master Mix (Applied Biosystems Part No. 4371357), 20X TaqMan 237 CNV assay, and 20x RNase P TaqMan Copy Number Reference Assay (Applied Biosystems Part No. 238 4403328) in a total volume of 20ul. The DNA amplification and quantification were carried out in a 239 QuantStudio 12K Flex instrument (Applied Biosystems) in a 96 well format with the following program: 240 50°C 2min, 95°C 10min followed by 40 cycles of 95°C 15sec, 60°C 1min. The results were analyzed 241 using the TaqMan CopyCaller software (Version 2.0) (Applied Biosystems).

242

#### 243 *Determine haplotypic contributions to diploid copy number*

244 For approximately sixty percent of the samples, only one combination of the structural forms 245 (eFigure 1 in **Supplement**) was possible based on the H1 and H2 genotypes, determined by the 238-bp 246 deletion, and the copy numbers of  $\alpha$ ,  $\beta$  and  $\gamma$ . For the rest of the samples, multiple haplotypic 247 combinations were possible. Therefore, we initially assigned an equal likelihood to all possible 248 haplotypic combinations that were consistent with the detected copy number of  $\alpha$ ,  $\beta$ , and  $\gamma$ . Then, the 249 following expectation-maximization (EM) loop described in the previous study<sup>14</sup> were repeated: from 250 the probabilistic inferences of structural form of 17q21.31 in each sample, we estimated an allele



268

269 *Linkage disequilibrium between structural forms of 17q21.31 and MAPT sub-haplotypes* 

270 To phase the structural forms of 17q21.31 together with *MAPT* sub-haplotypes, we encoded the



276

277 *Statistical Analysis* 

278 Statistical analyses were performed for the 4,076 individuals ( $N_{PSP} = 1,684$ ,  $N_{control} = 2,392$ ). For the 279 association of the copy numbers of α, β, and γ with PSP, logistic regression adjusting for sex and PC1-5 280 for population substracture was employed. Age was not adjusted in the regression model with following 281 considerations: first, more than half of the PSP cases have age missing (**Table 1**); second, controls 282 (average age, 81) was much older compared to PSP (average age, 63) and well over the mean age-of 283 onset for PSP which is 63 years<sup>28</sup>. Individuals with the H2H2 genotype are imbalanced (5 cases, 138) 284 controls) and with few cases, therefore, statistical analysis for this subgroup was not included.

285 To evaluate the association of the structural forms of 17q21.31 with PSP, each structural form with 286 allele frequency > 1% is compared with the rest of structural forms using logistic regression model 287 adjusting for sex and PC1-5. To evaluate the association of *MAPT* sub-haplotypes with PSP, each *MAPT* 288 sub-haplotypes with allele frequency > 1% was compared with the rest of sub-haplotypes using logistic 289 regression adjusting for sex and PC1-5.

290

### 291 **Results**

# <sup>292</sup>*The copy numbers of* α*,* β*, and* γ *and PSP risk*









309 \*Represents statistical significance (< 0.05)

310 We found no significant association for the copy numbers of α (OR, 0.9; 95%CI 0.81-1.00; *P*<sup>=</sup> 311 0.061) and β (OR, 0.9; 95%CI 0.81-1.01; *P* =0.064) with PSP when adjusting the allele count (0, 1, or 2) 312 of H2 (**Table 2**); however, individuals with more copies of α and β showed slightly lower odds ratio for 313 PSP. Similarly, no significance was observed for the copy numbers of  $\alpha$  and  $\beta$  when association analysis 314 was stratified by H1H1 or H1H2 genotype. Only under the regression model without adjusting H1 and H2, we observed statistically significant association for the copy numbers of α ( $P < 2 \times 10^{-16}$ ) and β ( $P =$ 316 0.011) with PSP. However, the observed significance mainly arises from their correlation with the H1 317 and H2 haplotypes, i.e., the increased copies (usually two copies) of  $\alpha$  and the absence of  $\beta$  duplication 318 in the H2 haplotype.

319

# 320 *Structural forms of 17q21.31 and PSP risk*



330

331 **Table 3. Structural forms of 17q21.31 and the risk of PSP**

		Frequency $(\% )$		
<b>Structural forms</b>	$PSP(N = 1,684)$	Control $(N = 2,392)$	Odds ratio	${\bf P}$
$H1\beta1\gamma1$	32.57	28.20	$1.21(1.10-1.33)$	$5.47 \times 10^{-5}$
$H1\beta1\gamma2$	21.94	16.99	$1.29(1.16-1.43)$	$1.35 \times 10^{-6}$
$H1\beta1\gamma3$	14.73	10.26	$1.45(1.27-1.65)$	$3.94 \times 10^{-8}$
$H1\beta1\gamma4$	1.93	1.28	$1.57(1.10-2.26)$	$1.35 \times 10^{-2}$
H1β2γ1	22.98	19.69	$1.24(1.11-1.38)$	$1.87 \times 10^{-4}$
$H2\alpha 1\gamma 2$	0.42	1.78	$0.23(0.12-0.40)$	$5.94 \times 10^{-7}$
$H2\alpha2\gamma2$	4.78	20.09	$0.19(0.16-0.23)$	$<$ 2 $\times$ $10^{-16}$

332 Haplotypes in less than 1% of individuals were excluded.

333 Odds ratio and *P* value were from logistic regression adjusting for PC1-5 and Sex.

334

#### 335 *Structural forms of 17q21.31 and MAPT sub-haplotypes*



		Sub-haplotype Frequency $(\% )$	<b>OR</b>	${\bf P}$
Haplotype		PSP ( $N = 1,684$ ) Control ( $N = 2,392$ )		
H1b	16.92	16.99	$1.01(0.90-1.14)$	0.84
H1c**	19.6	11.98	$1.79(1.58-2.04)$	$1.84 \times 10^{-19}$
$H1d**$	10.39	7.09	$1.52(1.29-1.79)$	$3.89 \times 10^{-7}$
H1e	8.76	8.07	$1.12(0.95-1.32)$	0.17
$H1g*$	2.67	1.80	$1.46(1.07-1.98)$	0.016
$H1h*$	5.23	4.03	$1.36(1.10-1.69)$	0.0053
H <sub>1</sub>	4.69	4.08	$1.17(0.94 - 1.46)$	0.15
H1j	1.28	1.21	$1.09(0.72 - 1.64)$	0.68
H11	2.91	3.22	$0.92(0.71-1.20)$	0.55
H1m	2.11	2.07	$1.08(0.78-1.47)$	0.64
$H10**$	4.13	1.53	$2.88(2.15-3.89)$	$2.77 \times 10^{-12}$
H <sub>1p</sub>	1.07	1.36	$0.80(0.52-1.21)$	0.30
H1q	1.22	0.86	$1.45(0.92 - 2.26)$	0.11
H1r	1.16	1.30	$0.92(0.60-1.39)$	0.69
H1u	2.64	2.34	$1.16(0.86-1.54)$	0.33
H1x	1.43	1.36	$0.98(0.67-1.44)$	0.93
H <sub>1y</sub>	1.54	1.51	$1.01(0.70-1.44)$	0.98
H1z	1.40	1.00	$1.41(0.93-2.14)$	0.11

343 **Table 4.** *MAPT* **sub-haplotypes defined by six SNVs and the risk of PSP**

344 *MAPT* sub-haplotypes in less than 1% of individuals were excluded.

345 \*Represents *MAPT* sub-haplotypes with a *P* <= 0.05 (nominal significant)



348

349 We examined the relationship between the structural forms of 17q21.31 (~1.5 Mb) and *MAPT* 350 sub-haplotypes (~150 Kb) through LD analysis. We identified two pairs with  $R^2 > 0.1$  (eTable 4 in **Supplement**): H1β1γ3 and H1c ( $\mathbb{R}^2 = 0.31$ ) and H1β2γ1 and H1b ( $\mathbb{R}^2 = 0.29$ ). This was confirmed by 352 the fact that 70% of H1β1γ3 are H1c and 56% of H1β2γ1 are H1b (**Fig. 1A**). Moreover, with additional 353 copies of γ in the H1, the proportion of *MAPT* sub-haplotypes with increased risk of PSP (i.e., H1c, H1d, 354 H1g, H1h, and H1o) increases from 34% (H1β1γ1) to 77% (H1β1γ4) (**Fig. 1A**). In contrast, the 355 proportion of *MAPT* sub-haplotypes with increased risk of PSP drops from 34% (H1β1γ1) to 11% 356 (H1β2γ1) with an additional copy of β (**Fig. 1A**). In individuals with H1H2 genotypes, no phasing is 357 needed before comparison, therefore, the association between the structural forms of 17q21.31 and 358 *MAPT* sub-haplotypes can be observed directly without phasing (**Fig. 1B**).



### 359

#### 360 **Fig. 1: Structural forms of 17q21.31 and** *MAPT* **sub-haplotypes**

361 Structural forms of 17q.21.31 in less than 1% of individuals were excluded. Structural forms with H2 362 background are also excluded since there is only one *MAPT* sub-haplotypes for H2. The number above 363 each bar is the total number of *haplotypes* for the specific structural form of 17q21.31 and the 364 percentage that are also *MAPT* sub-haplotypes (H1o, H1c, H1d, H1g, H1h) associated with increased 365 risk of PSP. Besides, the percentage of H1β1γ3 that is H1c and the percentage of of H1β2γ1 that is H1b 366 are displayed. A. In phased haplotypes from all samples, the proportion of *MAPT* sub-haplotypes in each 367 structural form of 17q21.31. **B.** In H1H2 individuals, the proportion of *MAPT* sub-haplotypes in each 368 structural form of 17q21.31.

369

### 370 **Discussion**

The H1 and H2 haplotypes on 17q21.31 is the strongest genetic risk factor for PSP<sup>7</sup>. The *MAPT* 

372 gene inside H1 and H2 showed haplotypic-specific expression and was considered as the possible cause



383 It should be noted that the copy numbers of  $\alpha$ ,  $\beta$ , and  $\gamma$  are correlated with H1 and H2. When 384 performing the association of the copy numbers of  $\alpha$ ,  $\beta$ , and  $\gamma$  with PSP in individuals with European 385 ancestry, previous studies demonstrated that the 205-Kb β region can only duplicate in the H1 haplotype, 386 the smaller 155-Kb  $\alpha$  region but not the entire  $\beta$  region duplicates in the H2 haplotype, and the 210-Kb  $\gamma$ 387 region usually duplicates only once in the H2 haplotype (eFigure 1 in **Supplement**)<sup>15,31</sup>. Therefore, it is 388 important to adjust the status of H1 and H2 and split analysis by individuals with H1H1 and H1H2 389 genotypes when performing the association of  $\alpha$ ,  $\beta$ , and  $\gamma$  with PSP. In terms of genomic position, the  $\alpha$ 390 region is included in  $\beta$  region, and parts of  $\beta$  and  $\gamma$  are overlapping with each other (eFigure 1 in <sup>391</sup>**Supplement**). When performing the association of α with PSP, we considered whenever there was a <sup>β</sup> 392 duplication there was also a  $\alpha$  duplication as  $\alpha$  region is included in β. Considering these factors, we

393 found that only  $\gamma$  is independently associated with risk of PSP, and the associations of  $\alpha$  and  $\beta$  with PSP 394 are due to their correlation with H1 and H2.

395 The influence of structural forms of 17q21.31 on the risk of PSP has never been examined before. In 396 this study, we found that all structural forms with H1 background were association with increased with 397 of PSP. Particularly, H1 with additional γ copies (H1β1γ2, H1β1γ3, and H1β1γ4) displayed a higher 398 odds ratio for PSP compared to H1β1γ1. In previous studies of *MAPT* sub-haplotypes, only a few 399 sub-haplotypes (i.e., H1c, H1d, H1o, and H1g) were associated with increased risk of PSP while other 400 sub-haplotypes displayed no differences against the rest of the population<sup>11,13</sup>. We replicated the 401 association of H1c, H1d, H1o and H1g with PSP and identified H1h with nominal significance. 402 Furthermore, we showed that the H1 haplotype with additional γ copies had more *MAPT* sub-haplotypes 403 that have higher risk of PSP (H1c, H1d, H1o, H1g and H1h), the proportion of *MAPT* sub-haplotypes 404 associated with PSP increased from 34% in H1β1γ1 to 77% in H1β1γ4.

#### 405 **Limitations**

406 Despite our finding of the importance of the copy number of  $\gamma$  duplication in the risk of PSP, there 407 are a few limitations in the current study. First, all our PSP samples are of European ancestry. It is 408 important to collect samples from other ancestries to validate the discovery in a genetically diverse 409 background. Second, not all PSP cases are pathologically confirmed: of the 1,684 individuals with PSP, 410 1,386 were autopsy confirmed. Finally, the association analysis needed to be replicated in an 411 independent dataset. Currently, the available resource for whole genome sequencing data in PSP is 412 limited. Therefore, future study focusing on  $\alpha$ , β, and γ regions using CNV array to replicate the findings

413 in a large independent cohorts might be helpful.

414





- 444
- 445 *Funding*

446 This work was supported by NIH 5UG3NS104095, the Rainwater Charitable Foundation, and 447 CurePSP. HW and PLC are supported by RF1-AG074328, P30-AG072979, U54-AG052427 and 448 U24-AG041689. TSC is supported by NIH K08AG065519 and the Larry L Hillblom Foundation 449 2021-A-005-SUP. YQS, AT, and JYT are supported by RF1-AG074328. KF was supported by CurePSP 450 685-2023-06-Pathway and K01 AG070326. MG is supported by P30 AG066511. BFG and KLN are 451 supported by P30 AG072976 and R01 AG080001. TGB and GES are supported by P30AG072980. IR is 452 supported by 2R01AG038791-06A, U01NS100610, R25NS098999, U19 AG063911-1 and 453 1R21NS114764-01A1. OR is support by U54 NS100693. DG is supported by P30AG062429. ALB is

454 supported by U19AG063911, R01AG073482, R01AG038791, and R01AG071756. BLM is supported 455 by P01 AG019724, R01 AG057234 and P0544014. VMV is supported by P01-AG-066597, 456 P01-AG-017586. HRM is supported by CurePSP, PSPA, MRC, and Michael J Fox Foundation. RDS is 457 supported by CurePSP, PSPA, and Reta Lila Weston Trust. JFC is supported by R01 AG054008, R01 458 NS095252, R01 AG060961, R01 NS086736, R01 AG062348, P30 AG066514, the Rainwater Charitable 459 Foundation / Tau Consortium, Karen Strauss Cook Research, and Scholar Award, Stuart Katz & Dr. Jane 460 Martin. AMG is supported by the Tau Consortium and U54-NS123746. YYL is supported by 461 U54-AG052427; U24-AG041689. LSW is supported by U01AG032984, U54AG052427, and 462 U24AG041689. GUH was funded by the Deutsche Forschungsgemeinschaft (DFG, German Research 463 Foundation) under Germany's Excellence Strategy within the framework of the Munich Cluster for 464 Systems Neurology (EXC 2145 SyNergy - ID 390857198); Deutsche Forschungsgemeinschaft (DFG, 465 HO2402/18-1 MSAomics); German Federal Ministry of Education and Research (BMBF, 01KU1403A 466 EpiPD; 01EK1605A HitTau; 01DH18025 TauTherapy). DHG is supported by 3UH3NS104095, Tau 467 Consortium. WPL is supported by RF1-AG074328; P30-AG072979; U54-AG052427; U24-AG041689. 468 Cases from Banner Sun Health Research Institute were supported by the NIH (U24 NS072026, P30 469 AG19610 and P30AG072980), the Arizona Department of Health Services (contract 211002, Arizona 470 Alzheimer's Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 471 05-901 and 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for 472 Parkinson's Research. The Mayo Clinic Brain Bank is supported through funding by NIA grants P50 473 AG016574, CurePSP Foundation, and support from Mayo Foundation.

474

### 475 *Acknowledgements*

476 This project is supported by CurePSP, courtesy of a donation from the Morton and Marcine 477 Friedman Foundation. We are indebted to the Biobanc-Hospital Clinic-FRCB-IDIBAPS and Center for 478 Neurodegenerative Disease Research at Penn for samples and data procurement. The PSP genetics study 479 group is a multisite collaboration including: German Center for Neurodegenerative Diseases (DZNE), 480 Munich; Department of Neurology, LMU Hospital, Ludwig-Maximilians-Universität (LMU), Munich, 481 Germany (Franziska Hopfner, Günter Höglinger); German Center for Neurodegenerative Diseases 482 (DZNE), Munich; Center for Neuropathology and Prion Research, LMU Hospital, 483 Ludwig-Maximilians-Universität (LMU), Munich, Germany (Sigrun Roeber, Jochen Herms); 484 Justus-Liebig-Universität Gießen, Germany (Ulrich Müller); MRC Centre for Neurodegeneration 485 Research, King's College London, London, UK (Claire Troakes); Movement Disorders Unit, Neurology 486 Department and Neurological Tissue Bank and Neurology Department, Hospital Clínic de Barcelona, 487 University of Barcelona, Barcelona, Catalonia, Spain (Ellen Gelpi; Yaroslau Compta); Department of 488 Neurology and Netherlands Brain Bank, Erasmus Medical Centre, Rotterdam, The Netherlands (John C. 489 van Swieten); Division of Neurology, Royal University Hospital, University of Saskatchewan, Canada 490 (Alex Rajput); Australian Brain Bank Network in collaboration with the Victorian Brain Bank Network, 491 Australia (Fairlie Hinton), Department of Neurology, Hospital Ramón y Cajal, Madrid, Spain (Justo 492 García de Yebenes). The acknowledgement of PSP cohorts is listed below, whereas the 493 acknowledgement of ADSP cohorts for control samples can be found in the supplementary materials.

494 The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of 495 the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and 496 NINDS. The data used for the analyses described in this manuscript were obtained from: 497 https://gtexportal.org/home/datasets the GTEx Portal on 1/27/2022. We also thank to Drs. Murray 498 Grossman and Hans Kretzschmar for their valuable contribution to this work.

499 AMP-AD (sa000011) data: Mayo RNAseq Study- Study data were provided by the following sources: 500 The Mayo Clinic Alzheimer's Disease Genetic Studies, led by Dr. Nilufer Ertekin-Taner and Dr. Steven 501 G. Younkin, Mayo Clinic, Jacksonville, FL using samples from the Mayo Clinic Study of Aging, the 502 Mayo Clinic Alzheimer's Disease Research Center, and the Mayo Clinic Brain Bank. Data collection 503 was supported through funding by NIA grants P50 AG016574, R01 AG032990, U01 AG046139, R01 504 AG018023, U01 AG006576, U01 AG006786, R01 AG025711, R01 AG017216, R01 AG003949, 505 NINDS grant R01 NS080820, CurePSP Foundation, and support from Mayo Foundation. Study data 506 includes samples collected through the Sun Health Research Institute Brain and Body Donation Program 507 of Sun City, Arizona. The Brain and Body Donation Program is supported by the National Institute of 508 Neurological Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's 509 Disease and Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's 510 Disease Core Center), the Arizona Department of Health Services (contract 211002, Arizona Alzheimer's 511 Research Center), the Arizona Biomedical Research Commission (contracts 4001, 0011, 05-901 and 512 1001 to the Arizona Parkinson's Disease Consortium) and the Michael J. Fox Foundation for Parkinson's 513 Research.

514 PSP-NIH-CurePSP-Tau (sa000015) data: This project was funded by the NIH grant UG3NS104095 and 515 supported by grants U54NS100693 and U54AG052427. Queen Square Brain Bank is supported by the 516 Reta Lila Weston Institute for Neurological Studies and the Medical Research Council UK. The Mayo 517 Clinic Florida had support from a Morris K. Udall Parkinson's Disease Research Center of Excellence 518 (NINDS P50 #NS072187), CurePSP and the Tau Consortium. The samples from the University of 519 Pennsylvania are supported by NIA grant P01AG017586. 520 PSP-CurePSP-Tau (sa000016) data: This project was funded by the Tau Consortium, Rainwater 521 Charitable Foundation, and CurePSP. It was also supported by NINDS grant U54NS100693 and NIA

522 grants U54NS100693 and U54AG052427. Queen Square Brain Bank is supported by the Reta Lila 523 Weston Institute for Neurological Studies and the Medical Research Council UK. The Mayo Clinic 524 Florida had support from a Morris K. Udall Parkinson's Disease Research Center of Excellence (NINDS 525 P50 #NS072187), CurePSP and the Tau Consortium. The samples from the University of Pennsylvania 526 are supported by NIA grant P01AG017586. Tissues were received from the Victorian Brain Bank, 527 supported by The Florey Institute of Neuroscience and Mental Health, The Alfred and the Victorian 528 Forensic Institute of Medicine and funded in part by Parkinson's Victoria and MND Victoria. We are 529 grateful to the Sun Health Research Institute Brain and Body Donation Program of Sun City, Arizona for 530 the provision of human biological materials (or specific description, e.g. brain tissue, cerebrospinal 531 fluid). The Brain and Body Donation Program is supported by the National Institute of Neurological 532 Disorders and Stroke (U24 NS072026 National Brain and Tissue Resource for Parkinson's Disease and 533 Related Disorders), the National Institute on Aging (P30 AG19610 Arizona Alzheimer's Disease Core



548 Study design: TSC, DD, GUH, JYT, DHG, GDS, and WPL. Sample collection, brain biospecimens,

- 549 and neuropathological examinations: TSC, CM, LM, AR, PPDD, NLB, MG, LDK, JCVS, ED, BFG,
- 550 KLN, CT, JGdY, ARG, TM, WHO, GR, UM, FH, TA, SR, PP, AB, AD, ILB, TGC, GES, LNH, IL, RR,
- 551 OR, DG, ALB, BLM, WWS, VMVD, EBL, CLW, HM, JH, RdS, JFC, AMG, GC, and DHG. Genotype
- 552 or phenotype acquisition: HW, TSC, VP, LVB, KF, AN, LSW, DHG, GDS, and WPL. Variant detection
- 553 and variant quality check: HW, TSC, VP, LVB, KF, YYL, and WPL. Statistical analyses and

- 554 interpretation of results: HW, YQS, AT, TSC, KF, AN, JYT, DHG, GDS, and WPL. Experimental
- 555 validation: BAD and PLC. Draft of the manuscript: HW, GDS, and WPL. All authors read, critically
- 556 revised, and approved the manuscript.

#### 557 **References**

- 558 1. Armstrong RA. Visual signs and symptoms of progressive supranuclear palsy. *Clin Exp Optom*. 559 2011;94(2):150-160. doi:10.1111/j.1444-0938.2010.00504.x
- 560 2. Lukic MJ, Respondek G, Kurz C, et al. Long-Duration Progressive Supranuclear Palsy: Clinical 561 Course and Pathological Underpinnings. *Ann Neurol*. 2022;92(4):637-649.
- 562 3. Ali F, Martin PR, Botha H, et al. Sensitivity and specificity of diagnostic criteria for progressive 563 supranuclear palsy. *Mov Disord*. 2019;34(8):1144-1153.
- 564 4. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for 565 Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). *Neurology*. 566 1994;44(11):2015-2015.
- 567 5. Kovacs GG, Lukic MJ, Irwin DJ, et al. Distribution patterns of tau pathology in progressive 568 supranuclear palsy. *Acta Neuropathol (Berl)*. 2020;140(2):99-119. doi:10.1007/s00401-020-02158-2
- 569 6. Stamelou M, Respondek G, Giagkou N, Whitwell JL, Kovacs GG, Höglinger GU. Evolving 570 concepts in progressive supranuclear palsy and other 4-repeat tauopathies. *Nat Rev Neurol*. 571 2021;17(10):601-620. doi:10.1038/s41582-021-00541-5
- 572 7. Baker M, Litvan I, Houlden H, et al. Association of an extended haplotype in the tau gene with 573 progressive supranuclear palsy. *Hum Mol Genet*. 1999;8(4):711-715.
- 574 8. Höglinger GU, Melhem NM, Dickson DW, et al. Identification of common variants influencing risk 575 of the tauopathy progressive supranuclear palsy. *Nat Genet*. 2011;43(7):699-705.
- 576 9. Wang H, Chang TS, Dombroski BA, et al. Whole-Genome Sequencing Analysis Reveals New 577 Susceptibility Loci and Structural Variants Associated with Progressive Supranuclear Palsy. *medRxiv*. 578 Published online 2023:2023-12.
- 579 10. Conrad C, Andreadis A, Trojanowski JQ, et al. Genetic evidence for the involvement of τ in progressive supranuclear palsy. Ann Neurol. 1997;41(2): 277-281. doi:10.1002/ana.410410222 580 progressive supranuclear palsy. *Ann Neurol*. 1997;41(2):277-281. doi:10.1002/ana.410410222
- 581 11. Heckman MG, Brennan RR, Labbé C, et al. Association of MAPT subhaplotypes with risk of 582 progressive supranuclear palsy and severity of tau pathology. *JAMA Neurol*. 2019;76(6):710-717.
- 583 12. Heckman MG, Kasanuki K, Brennan RR, et al. Association of MAPT H1 subhaplotypes with 584 neuropathology of lewy body disease. *Mov Disord*. 2019;34(9):1325-1332. doi:10.1002/mds.27773
- 585 13. Pittman AM, Myers AJ, Abou-Sleiman P, et al. Linkage disequilibrium fine mapping and haplotype

- 586 association analysis of the tau gene in progressive supranuclear palsy and corticobasal degeneration. 587 *J Med Genet*. 2005;42(11):837-846.
- 588 14. Boettger LM, Handsaker RE, Zody MC, McCarroll SA. Structural haplotypes and recent evolution 589 of the human 17q21. 31 region. *Nat Genet*. 2012;44(8):881-885.
- 590 15. Steinberg KM, Antonacci F, Sudmant PH, et al. Structural diversity and African origin of the 17q21. 591 31 inversion polymorphism. *Nat Genet*. 2012;44(8):872-880.
- 592 16. Kuzma A, Valladares O, Cweibel R, et al. NIAGADS: The NIA Genetics of Alzheimer's Disease 593 Data Storage Site. *Alzheimers Dement*. 2016;12(11):1200-1203. doi:10.1016/j.jalz.2016.08.018
- 594 17. Beecham GW, Bis JC, Martin ER, et al. The Alzheimer's Disease Sequencing Project: study design 595 and sample selection. *Neurol Genet*. 2017;3(5).
- 596 18. Jin Y, Schaffer AA, Feolo M, Holmes JB, Kattman BL. GRAF-pop: a fast distance-based method to 597 infer subject ancestry from multiple genotype datasets without principal components analysis. *G3*  598 *Bethesda Md*. 2019;9(8):2447-2461.
- 599 19. Manichaikul A, Mychaleckyj JC, Rich SS, Daly K, Sale M, Chen WM. Robust relationship 600 inference in genome-wide association studies. *Bioinformatics*. 2010;26(22):2867-2873.
- 601 20. Wang H, Dombroski BA, Cheng PL, et al. Structural Variation Detection and Association Analysis 602 of Whole-Genome-Sequence Data from 16,905 Alzheimer's Diseases Sequencing Project Subjects. 603 *medRxiv*. Published online 2023.
- 604 21. Cantsilieris S, Western PS, Baird PN, White SJ. Technical considerations for genotyping 605 multi-allelic copy number variation (CNV), in regions of segmental duplication. *BMC Genomics*. 606 2014;15(1):329. doi:10.1186/1471-2164-15-329
- 607 22. Handsaker RE, Van Doren V, Berman JR, et al. Large multiallelic copy number variations in humans. 608 *Nat Genet*. 2015;47(3):296-303.
- 609 23. Sharp AJ, Locke DP, McGrath SD, et al. Segmental duplications and copy-number variation in the 610 human genome. *Am J Hum Genet*. 2005;77(1):78-88.
- 611 24. Suvakov M, Panda A, Diesh C, Holmes I, Abyzov A. CNVpytor: a tool for copy number variation 612 detection and analysis from read depth and allele imbalance in whole-genome sequencing. 613 *Gigascience*. 2021;10(11):giab074.
- 614 25. Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine learning in Python. *J Mach*  615 *Learn Res*. 2011;12:2825-2830.

- 616 26. Lee WP, Choi SH, Shea MG, et al. Association of Common and Rare Variants with Alzheimer's 617 Disease in over 13,000 Diverse Individuals with Whole-Genome Sequencing from the Alzheimer's 618 Disease Sequencing Project. *medRxiv*. Published online 2023:2023-09.
- 619 27. Delaneau O, Zagury JF, Robinson MR, Marchini JL, Dermitzakis ET. Accurate, scalable and 620 integrative haplotype estimation. *Nat Commun*. 2019;10(1):5436.
- 621 28. Rajput A, Rajput AH. Progressive Supranuclear Palsy: Clinical Features, Pathophysiology and 622 Management. *Drugs Aging*. 2001;18(12):913-925. doi:10.2165/00002512-200118120-00003
- 623 29. Rademakers R, Melquist S, Cruts M, et al. High-density SNP haplotyping suggests altered 624 regulation of tau gene expression in progressive supranuclear palsy. *Hum Mol Genet*. 625 2005;14(21):3281-3292.
- 626 30. Caffrey TM, Joachim C, Paracchini S, Esiri MM, Wade-Martins R. Haplotype-specific expression of 627 exon 10 at the human MAPT locus. *Hum Mol Genet*. 2006;15(24):3529-3537.
- 628 31. Sudmant PH, Kitzman JO, Antonacci F, et al. Diversity of human copy number variation and 629 multicopy genes. *Science*. 2010;330(6004):641-646.